Xenothera

Xenothera is a clinical-stage biotech with a unique focus on engineering polyclonal antibodies. Its core technology, glyco-humanization (GH), removes non-human sugar antigens from antibodies derived from animals, aiming to create multispecific, low-immunogenicity therapies. The company has built an active pipeline targeting solid tumors, T-cell lymphomas, and infectious diseases, with its lead oncology candidate, XON7, already in clinical trials since 2023. Backed by a seasoned leadership team and strategic collaborations, Xenothera is positioning itself as an innovator in complex antibody therapeutics.

Glyco-Humanized Polyclonal Antibody (GH-pAb) platform that removes xeno-antigens (e.g., Neu5Gc) from animal-derived polyclonal antibodies to create low-immunogenicity, multispecific therapeutics with multiple mechanisms of action (CDC, ADCC, ADCP, apoptosis).

Xenothera competes in the broad antibody therapeutics market dominated by large pharma and biotechs focused on monoclonal and bispecific antibodies. Its direct competition is limited, as few companies are advancing engineered polyclonal antibodies, but it must prove its platform's superiority or complementarity against these entrenched, validated modalities.